SCHEMBL25487571

SCHEMBL25487571

Cc1ccc2c(ccc3sc(C)c(C)c32)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
CYP1A2 P05177 4/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CDK1 P06493 4/20 0.34
MAPKAPK2 P49137 4/20 0.34
RIPK2 O43353 1/20 0.34
CCNB2 O95067 1/20 0.34
ABCB11 O95342 1/20 0.34
PIM1 P11309 1/20 0.34
CCNB1 P14635 1/20 0.34
PHKG2 P15735 1/20 0.34
AXL P30530 1/20 0.34
CDK5 Q00535 1/20 0.34
MERTK Q12866 1/20 0.34
PRKAA1 Q13131 1/20 0.34
CAMK2B Q13554 1/20 0.34
CDK5R1 Q15078 1/20 0.34
MAPKAPK3 Q16644 1/20 0.34
MAPKAPK5 Q8IW41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25487572 0.83 ALDH1A1 (0.36) ALDH1A1CYP1A2NPC1RAB9ACDK1
SCHEMBL25487535 0.83 LMNA (0.37) ALDH1A1CYP1A2NPC1RAB9ACDK1
SCHEMBL25487994 0.74 P2RX7 (0.35) ALDH1A1KDM1ASMN1; SMN2MEN1KMT2A
SCHEMBL25487525 0.72 P2RX7 (0.36) KDM1A
SCHEMBL8571925 0.72 ALDH1A1 (0.53) ALDH1A1CYP1A2RAB9ALMNAKDM4E
SCHEMBL25487714 0.70 KDM4E (0.47) ALDH1A1NPC1RAB9AKDM4EPOLB
SCHEMBL31216692 0.69 HSD17B10 (0.50) ALDH1A1CYP1A2NPC1RAB9AKDM4E
SCHEMBL19916905 0.69 HSD17B10 (0.50) ALDH1A1CYP1A2NPC1RAB9AKDM4E
SCHEMBL25487585 0.68 TRPM8 (0.39) ALDH1A1NPC1RAB9ALMNAKDM4E
SCHEMBL25487830 0.68 LIMK1 (0.35) ALDH1A1NPC1RAB9ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655257-B2 MK2 inhibitors, synthesis thereof, and intermediates thereto CELGENE CAR LLC (BM) 2023-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655257-B2 MK2 inhibitors, synthesis thereof, and intermediates thereto WEE2, WEE1, CDK2 ALDH1A1 3405/4885CYP1A2 415/4885NPC1 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.